Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT5 | Q92993 | 10/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 10/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 9/20 | 0.40 |
| ▸ | KAT7 | O95251 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449855 | 0.87 | KAT5 (0.49) | KAT5KAT8KAT6AKAT7 | |
| SCHEMBL24449543 | 0.86 | KAT5 (0.39) | KAT5KAT8KAT6AKAT7 | |
| SCHEMBL24449537 | 0.85 | KAT6A (0.38) | KAT5KAT8KAT6AKAT7 | |
| SCHEMBL24449538 | 0.85 | KAT6A (0.41) | KAT5KAT8KAT6AKAT7 | |
| SCHEMBL24449850 | 0.79 | KAT6A (0.49) | KAT5KAT8KAT6AKAT7 | |
| SCHEMBL24449769 | 0.78 | KAT6A (0.50) | KAT5KAT8KAT6AKAT7 | |
| SCHEMBL25946915 | 0.76 | KAT8 (0.51) | KAT5KAT8KAT6A | |
| SCHEMBL25946901 | 0.74 | CNR1 (0.38) | KAT5KAT8KAT6AKAT7 | |
| SCHEMBL24449396 | 0.72 | KAT6A (0.46) | KAT5KAT8KAT6AKAT7 | |
| SCHEMBL24449856 | 0.70 | KAT6A (0.44) | KAT5KAT6AKAT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | KAT5 12/4885KAT8 6/4885KAT6A 3/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | KAT5 12/4885KAT8 6/4885KAT6A 3/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | KAT5 12/4885KAT8 6/4885KAT6A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.